Suppr超能文献

复方局部用阿米替林治疗神经性疼痛:从复方基质中的体外释放及其与临床疗效的潜在相关性

Compounded Topical Amitriptyline for Neuropathic Pain: In Vitro Release from Compounding Bases and Potential Correlation with Clinical Efficacy.

作者信息

Shakshuki Ayah, Yeung Pollen, Agu Remigius U

机构信息

, BScPharm, MScPharm, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, BScPharm, PhD, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, BPharm, MPharm, PhD, is with the College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.

出版信息

Can J Hosp Pharm. 2020 Mar-Apr;73(2):133-140. Epub 2020 Apr 1.

Abstract

BACKGROUND

Topical amitriptyline has been described as having mixed clinical efficacy for neuropathic pain. A few case reports using higher concentrations of this compound found clinical benefit, but many of these studies did not describe the components used in formulating the amitriptyline preparations.

OBJECTIVE

To generate reproducible clinical measures of the characteristics of amitriptyline diffusion from selected compounding bases, to support a scientific approach to base selection when compounding this drug for neuropathic pain.

METHODS

Amitriptyline hydrochloride (1%, 5%, and 10%) was compounded with 3 proprietary compounding bases: Lipoderm base, Emollient Cream, and Mediflo 30 pluronic lecithin organogel (PLO) gel. In vitro release of the drug from each base and subsequent permeation across artificial human skin were investigated with the Franz diffusion system. Amitriptyline release mechanisms were determined with kinetic models. How quickly and to what extent the drug leaves each base to diffuse through the skin were characterized by determining steady-state flux, cumulative permeation, and lag times.

RESULTS

Release of amitriptyline was significantly higher from the Mediflo PLO gel than from the Lipoderm base or Emollient Cream ( < 0.05). Mean cumulative drug release after 24 h, from the 10% formulation, was 23.9% (standard deviation [SD] 4.1%) for Lipoderm base, 41.8% (SD 3.1%) for Emollient Cream, and 53.2% (SD 7.7%) for Mediflo PLO gel. A high percentage of amitriptyline was retained in all 3 bases. Although amitriptyline release was highest with Mediflo PLO gel, this base resulted in significantly lower cumulative permeation relative to Lipoderm base and Emollient Cream ( < 0.05). There was a strong overall correlation between amitriptyline concentration, lag time, and flux. Higher concentrations were associated with significantly lower lag times and increased flux. The highest lag time and flux were observed for Mediflo PLO gel.

CONCLUSION

These data indicate that the therapeutic effectiveness of compounded amitriptyline for neuropathic pain depends on its diffusion out of the compounding bases and penetration through the skin.

摘要

背景

局部使用阿米替林治疗神经性疼痛的临床疗效存在差异。少数使用高浓度该化合物的病例报告显示有临床益处,但其中许多研究并未描述用于配制阿米替林制剂的成分。

目的

生成从选定的复方基质中扩散出的阿米替林特性的可重复临床测量值,以支持在为神经性疼痛配制该药物时选择基质的科学方法。

方法

将盐酸阿米替林(1%、5%和10%)与3种专利复方基质混合:Lipoderm基质、润肤霜和Mediflo 30普朗尼克卵磷脂有机凝胶(PLO)凝胶。使用Franz扩散系统研究药物从每种基质中的体外释放以及随后透过人造人皮的渗透情况。用动力学模型确定阿米替林的释放机制。通过测定稳态通量、累积渗透和滞后时间来表征药物离开每种基质并扩散穿过皮肤的速度和程度。

结果

Mediflo PLO凝胶中阿米替林的释放量显著高于Lipoderm基质或润肤霜(<0.05)。对于10%的制剂,24小时后Lipoderm基质的平均累积药物释放量为23.9%(标准差[SD]4.1%),润肤霜为41.8%(SD 3.1%),Mediflo PLO凝胶为53.2%(SD 7.7%)。所有3种基质中都保留了高比例的阿米替林。尽管Mediflo PLO凝胶中阿米替林的释放量最高,但与Lipoderm基质和润肤霜相比,该基质导致的累积渗透量显著更低(<0.05)。阿米替林浓度、滞后时间和通量之间存在很强的总体相关性。较高浓度与显著更低的滞后时间和增加的通量相关。Mediflo PLO凝胶的滞后时间和通量最高。

结论

这些数据表明,配制的阿米替林治疗神经性疼痛的疗效取决于其从复方基质中扩散出来并穿透皮肤的情况。

相似文献

6
Compounded gabapentin for neuropathic pain: Stability and beyond-use date (BUD) in some commonly used bases.
J Am Pharm Assoc (2003). 2019 Jul-Aug;59(4):514-520. doi: 10.1016/j.japh.2019.02.012. Epub 2019 Apr 9.
10
Characterization of the Percutaneous Absorption of Ketoprofen Using the Franz Skin Finite Dose Model.
Postgrad Med. 2016;128(2):262-7. doi: 10.1080/00325481.2016.1144448. Epub 2016 Feb 7.

引用本文的文献

2
Recent Progress in Gels for Neuropathic Pain.
Gels. 2023 May 16;9(5):417. doi: 10.3390/gels9050417.
3
[Not Available].
Can J Hosp Pharm. 2020 Mar-Apr;73(2):103-104. Epub 2020 Apr 1.
4
Medication Safety-A Global Health Priority.
Can J Hosp Pharm. 2020 Mar-Apr;73(2):101-102. Epub 2020 Apr 1.

本文引用的文献

1
Topical treatments for diabetic neuropathic pain.
Exp Ther Med. 2019 Mar;17(3):1963-1976. doi: 10.3892/etm.2019.7173. Epub 2019 Jan 15.
3
Systematic review of topical amitriptyline for the treatment of neuropathic pain.
J Clin Pharm Ther. 2015 Oct;40(5):496-503. doi: 10.1111/jcpt.12297. Epub 2015 Jun 7.
5
Prediction of skin permeation by chemical compounds using the artificial membrane, Strat-M™.
Eur J Pharm Sci. 2015 Jan 25;67:113-118. doi: 10.1016/j.ejps.2014.11.002. Epub 2014 Nov 14.
7
Neuropathic pain: mechanisms and their clinical implications.
BMJ. 2014 Feb 5;348:f7656. doi: 10.1136/bmj.f7656.
8
Skin matters: identifying pain mechanisms and predicting treatment outcomes.
Neurol Res Int. 2013;2013:329364. doi: 10.1155/2013/329364. Epub 2013 May 21.
9
Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline.
Case Rep Med. 2012;2012:471835. doi: 10.1155/2012/471835. Epub 2012 Jul 18.
10
High doses of topical amitriptyline in neuropathic pain: two cases and literature review.
Pain Pract. 2012 Feb;12(2):148-53. doi: 10.1111/j.1533-2500.2011.00477.x. Epub 2011 Jun 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验